Zusammenfassung
Bei etwa 2–5 % aller Patienten mit Multipler Sklerose tritt der erste Schub in der Kindheit oder Jugend auf (Pohl et al. 2008). Der Begriff „pädiatrische MS“ (in der Folge auch „juvenile MS“ genannt) bezieht sich entsprechend den Konsensuskriterien der „International Pediatric MS Study Group“ (IPMSSG) auf „Kinder“ (jünger als 10 Jahre) und „Jugendliche“ (10 Jahre und älter, bis vor dem 18. Geburtstag) (Krupp et al. 2007). In einer österreichweiten Erhebung konnte festgestellt werden, dass bei etwa 8 % aller Patienten bereits vor dem 18. Lebensjahr MS-spezifische Symptome auftreten, dass es aber doppelt so lange wie bei Erwachsenen dauert, bis die Diagnose einer MS gestellt wird (Bajer-Kornek et al. 2008).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Adams A, Tyor WR, Holden KR (1999) Interferon beta-1a and childhood multiple sclerosis. Pediatric Neurology 21:481–483
Amato MP, Goretti B, Ghezzi A et al (2008) Cognitive and psychosocial features of childhood and juvenile MS. Neurology 70:1891–1897
Bajer-Kornek B, Baumhackl U, Vass K (2009) Epidemiology of paediatric-onset multiple sclerosis in Austria. Multiple Sclerosis 15:38 (suppl. 2)
Banwell B, Reder AT, Krupp L et al (2006) Safety and tolerability of interferon beta-1b in pediatric multiple sclerosis. Neurology 66:472–476
Banwell B, Krupp L, Kennedy J et al (2007) Clinical features and viral serologies in children with multiple sclerosis: a multinational observational study. Lancet Neurology 6:773–781
Callen DJ, Shroff MM, Branson HM et al (2009) Role of MRI in the differentiation of ADEM from MS in children. Neurology 72:968–973
Chitnis T, Tenembaum S, Banwell B et al (2012) Consensus statement: evaluation of new and existing therapeutics for pediatric multiple sclerosis. Multiple Sclerosis 18:116–127
Ghezzi A (2005) Immunomodulatory treatment of early onset multiple sclerosis: results of an Italian co-operative study. Neurological Schience 26:183–186
Ghezzi A, Amato MP, Capobianco M et al (2005) Disease-modifying drugs in childhood-juvenile multiple sclerosis: results of an Italian cooperative study. Multiple Sclerosis 11:420–424
Ghezzi A, Amato MP, Annovazzi P et al (2009) Long-term results of immunomodulatory treatment in children and adolescents with multiple sclerosis: the Italian experience. Neurological Science 30:193–199
Ghezzi A, Banwell B, Boyko A et al (2010) The management of multiple sclerosis in children: an European view. Multiple Sclerosis 16:1258–1267
Gorman MP, Healy PC, Polgar-Turcsanyi M, Chitnis T (2009) Increased relapse rate in pediatric-onset compared with adult-onset multiple sclerosis. Archives of Neurology 66:54–59
Kornek B, Schmitl B, Vass K et al. (2012) Evaluation of the 2010 McDonald multiple sclerosis criteria in children with a clinically isolated syndrome. Mult Scler Apr 23 (Epub ahead of print)
Krupp LB, Banwell B, Tenembaum S (2007) Consensus definitions proposed for pediatric multiple sclerosis and related disorders. Neurology 68:7–12
Kuntz NL, Chabas D, Weinstock-Guttman B et al (2010) Treatment of multiple sclerosis in children and adolescents. Expert Opin Pharmacother 11:505–520
Mikaeloff Y, Adamsbaum C, Husson B et al (2004) MRI prognostic factors for relapse after acute CNS inflammatory demyelination in childhood. Brain 127:1942–1947
Mikaeloff Y, Caridade G, Tardieu M, Suissa S behalf of the KIDSEP study group of the French Neuropediatric Society (2008) Effectiveness of early beta interferon on the first attack after confirmed multiple sclerosis: A comparative cohort study. European Journal of Paediatric Neurology 12:205–208
Pohl D, Rostasy K, Reiber H, Hanefeld F (2004) CSF characteristics in early-onset multiple sclerosis. Neurology 63:1966–1967
Pohl D, Hennemuth I, von Kries R, Hanefeld F (2007) Pediatric Multiple Sclerosis and Acute Disseminated Encephalomyelitis in Germany: Results of a Nation-wide Survey. European Journal of Pediatrics 166:405–412
Pohl D (2008) Epidemiology, immunopathogenesis and management of pediatric central nervous system inflammatory demyelinating conditions. Current Opinion in Neurology 21:366–372
Polman CH, Reingold SC, Banwell B et al (2011) Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Annals of Neurology 69:292–302
Renoux C, Vukusic S, Mikaeloff Y et al (2007) Natural history of multiple sclerosis with childhood onset. New England Journal of Medicine 356:2603–2613
Schilling S, Haertel C, Sperner J (2002) Follow-up of interferon beta-1b treatment in a 15-year-old patient with secondary progressive multiple sclerosis. Neuropediatrics 33:A31
Waldman AT, Gorman MP, Rensel MR et al (2011) Management of pediatric central nervous system demyelinating disorders: consensus of United States neurologists. Journal of Child Neurology 26:675–682
Yeh EA, Waubant E, Krupp LB, Ness J, Chitnis T, Kuntz N et al (2011) Multiple sclerosis therapies in pediatric patients with refractory multiple sclerosis. Archives of Neuroly 68:437–444
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer-Verlag Wien
About this chapter
Cite this chapter
Bajer-Kornek, B. (2013). Betaferon® bei Kindern und Jugendlichen. In: Berger, T., Linnebank, M., Wiendl, H. (eds) Betaferon®. Springer, Vienna. https://doi.org/10.1007/978-3-7091-1766-8_9
Download citation
DOI: https://doi.org/10.1007/978-3-7091-1766-8_9
Published:
Publisher Name: Springer, Vienna
Print ISBN: 978-3-7091-1765-1
Online ISBN: 978-3-7091-1766-8
eBook Packages: Medicine (German Language)